Smallcap Healthcare Takeover Targets - AFR

To compound the great news today, this was an interesting article by the AFR yesterday on the boom of investments going into smallcap healthcare stocks over the past year (specifically $3.25B in the past 6 months) and growing trend towards biotech investments. I found this quote particularly interesting from the article.

https://www.copyright link/companies/healthcare-and-fitness/small-cap-healthcare-stocks-surge-to-billion-dollar-plays-20190929-p52vx1

"Post-phase two trials is considered a sweet spot for big pharma companies looking to make acquisitions, as the new therapies or products have already had some rigorous testing and there's data suggesting its likelihood of success. Once stage three trials have been completed, the assets are much more expensive to buy.There is also another wave of small cap biotech stocks going through stage two trials at the moment which investors could look at closely in the next few years, including Dimerix, Immutep, Starpharma and Antisense Therapeutics."

Given that BIT fits the above category of post phase 2 biotech - hopefully it'll mean some good news for us holders too in the upcoming year/s.

GLTAH.